GlassScriptPhysician profile
Cameron Thomasson
NPI 1205368230
$28,297.43
in general payments reported to CMS, 2019-2025
28 companies · $2,529 in 2025
The $2,529 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,955 · 2022: $6,713 · 2023: $4,452 · 2024: $4,649 · 2025: $2,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,250 · Food and Beverage: $5,086 · Travel and Lodging: $230 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,250.00 |
| Food and Beverage | $5,085.93 |
| Travel and Lodging | $229.61 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21,822.72 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $956.19 | 2021-2025 | |
| Pfizer INC. | $737.59 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.67 | 2022-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $515.01 | 2021-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $486.12 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $418.49 | 2021-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $312.69 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $297.10 | 2021-2025 | Cds - Mct/Cem Monitoring, Latitude Communicator Power Supply |
| E.R. Squibb & Sons, L.L.C. | $293.02 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $289.30 | 2021-2025 | Repatha, Repatha |
| Cvrx, INC. | $269.94 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $230.39 | 2021-2024 | Xarelto |
| Philips North America LLC | $187.31 | 2022-2025 | Event |
| Scpharmaceuticals INC. | $141.81 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $124.77 | 2021-2024 | Jot Dx |
| Bridgebio Pharma, INC. | $104.14 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $67.19 | 2023 | |
| Impulse Dynamics (USA) INC. | $62.06 | 2023 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $45.00 | 2023-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $34.31 | 2025 | |
| Medtronic, INC. | $31.46 | 2022 | |
| Cardiva Medical, INC. | $30.38 | 2025 | Cardiva Vascade 6/7f Vcs |
| Kiniksa Pharmaceuticals International, Plc | $30.01 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $23.41 | 2021 | |
| Daxor Corporation | $22.25 | 2024 | Bva-100 |
| Esperion Therapeutics, INC. | $17.11 | 2025 | Nexletol |
| Convatec INC. | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Thomasson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.